News & Updates

Show Multimedia Only

Early detection of PAH in connective tissue diseases: Why and how?

27 Dec 2024 by

Pulmonary arterial hypertension (PAH) is a severe complication of connective tissue diseases (CTDs). At the International Conference of Chinese Rheumatologists (ICCR) 2024, Dr Yeon-Ah Lee of the Kyung Hee University, Seoul, South Korea, emphasized the importance of screening and early detection of PAH in patients with CTDs and provided practical guidance for rheumatologists on screening for CTD-PAH, particularly in patients with systemic sclerosis (SSc) and systemic lupus erythematosus (SLE).

Early detection of PAH in connective tissue diseases: Why and how?

27 Dec 2024

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

25 Dec 2024

ATTD-ASIA 2024, held recently in Singapore, was a huge success, with nearly 800 delegates from 49 countries gracing the event. ATTD-Asia 2024 chair, Professor Moshe Phillip, said the event brought together top diabetes experts to ensure patients can access the latest technologies and treatments for diabetes. MIMS Doctor reports highlights and snippets from the conference.

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

25 Dec 2024

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

20 Dec 2024

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

20 Dec 2024

Use of an ARPI in combination with ADT in a patient with mHSPC

19 Dec 2024 by

A 74-year-old male presented with back pain, right hip pain, and right lower limb weakness in December 2023. He was a chronic smoker and had impaired fasting glucose that was controlled with diet. Work-up in mainland China with CT scan revealed multiple osteolytic lesions in the pelvis and bony spine. Blood test showed elevated serum prostate-specific antigen (PSA) level >300 ng/mL. He was on etoricoxib and acetaminophen for analgesia.

Use of an ARPI in combination with ADT in a patient with mHSPC

19 Dec 2024

CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC

13 Dec 2024 by

The phase III CROWN trial previously showed that first-line treatment with lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), provided significant survival benefits vs crizotinib in patients with treatment-naïve, advanced, ALK-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer, CROWN investigators discussed the patterns of progression and management of adverse events (AEs) associated with lorlatinib after 5 years of follow-up.

CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC

13 Dec 2024

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

10 Dec 2024

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

10 Dec 2024

First-line use of SGLT2 inhibitor as GDMT in a patient with HFpEF

09 Dec 2024 by

A 75-year-old female with a history of hypertension, diabetes, hyperlipidaemia, paroxysmal atrial fibrillation treated with apixaban (5 mg BID), and tachy-brady syndrome (for which a pacemaker was implanted in August 2022) was hospitalized due to acute shortness of breath (SoB) in November 2022.

First-line use of SGLT2 inhibitor as GDMT in a patient with HFpEF

09 Dec 2024

AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment

09 Dec 2024 by

At the Alzheimer’s Association International Conference (AAIC) 2024 held in Philadelphia, US, researchers presented latest findings on the use of the dual-acting, anti–amyloid beta (Aβ) protofibril antibody, lecanemab, for treatment of early Alzheimer’s disease (AD). Topics covered included the paradoxical brain volume changes associated with anti-amyloid immunotherapy and the 3-year clinical efficacy results of continuous lecanemab treatment from the phase III Clarity AD study.

AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment

09 Dec 2024

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

04 Dec 2024

Landmark analysis of the phase III TITAN study shows that apalutamide plus ADT has resulted in UL PSA in a larger proportion of mHSPC patients than treatment with ADT alone. Furthermore, deeper and earlier UL PSA decline was associated with improved outcomes, including rPFS and OS.

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

04 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Early detection of PAH in connective tissue diseases: Why and how?

Early detection of PAH in connective tissue diseases: Why and how?

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

Use of an ARPI in combination with ADT in a patient with mHSPC

Use of an ARPI in combination with ADT in a patient with mHSPC

CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC

CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

First-line use of SGLT2 inhibitor as GDMT in a patient with HFpEF

First-line use of SGLT2 inhibitor as GDMT in a patient with HFpEF

AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment

AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment

Clinical considerations for patients at high risk for progression to severe COVID-19

Clinical considerations for patients at high risk for progression to severe COVID-19

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC